SCHEMBL158246

SCHEMBL158246

CC(C)CCC[C@@H](C)[C@H]1CCC2C3CC=C4CC(OS(=O)(=O)O)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 3/20 1.00
NR1H3 Q13133 3/20 0.83
POLA1 P09884 1/20 0.74
OSBP P22059 3/20 0.71
USP2 O75604 2/20 0.71
RORC P51449 2/20 0.71
LMNA P02545 1/20 0.71
ABCB1 P08183 1/20 0.71
OSBP2 Q969R2 1/20 0.71
GRIN2A Q12879 2/20 0.63
GRIN2D O15399 1/20 0.63
GRIN2B Q13224 1/20 0.63
GRIN2C Q14957 1/20 0.63
GRIN1 Q05586 1/20 0.61
GBA1 P04062 2/20 0.60
UGCG Q16739 2/20 0.60
GBA2 Q9HCG7 2/20 0.60
NPC1L1 Q9UHC9 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161397 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL3509637 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL2304848 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL192029 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL25063545 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL22077526 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL25063542 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL16248291 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL21334348 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2
SCHEMBL21824301 1.00 CYP46A1 (1.00) CYP46A1NR1H3POLA1OSBPUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115129-A1 METHOD FOR INCREASING EFFECTIVE POLYPHENOL COMPONENTS USING HIGH-TEMPERATURE AND PRESSURIZATION STEAM EXTRACTION METHOD SUMSUMBIOCO LTD (KR) 2026-04-30 US claimed
US-20250281459-A1 LIPIDS, FORMULATIONS, AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-09-11 US claimed
US-20250186339-A1 COMPOSITION FOR INTRAORAL DELIVERY OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS SCHWARZ JOSEPH (CA) 2025-06-12 US claimed
US-20240269229-A1 NOVEL LIPOPEPTIDE FORMULATION ADVAPHARM GMBH (DE) 2024-08-15 US claimed
WO-2023211934-A1 LIPIDS, FORMULATIONS, AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-11-02 WO claimed
WO-2023041588-A1 NOVEL LIPOPEPTIDE FORMULATION ADVAPHARM GMBH (DE) 2023-03-23 WO claimed
EP-3474953-B1 SUBSTANCE MIXTURE CONTAINING GLYCOSAMINOGLYCAN, METHOD FOR PRODUCING SAME AND USE OF SAME FACH DR CHRISTIAN (DE) 2022-11-16 EP claimed
US-20220228171-A1 COMPOSITIONS AND PRODUCTION OF NICKED CLOSED-ENDED DNA VECTORS GENERATION BIO CO. 2022-07-21 US claimed
WO-2022153211-A1 LIPOSOMAL COMPOSITION OF A CAMPTOTHECIN DERIVATIVE SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2022-07-21 WO claimed
EP-3999646-A1 COMPOSITIONS AND PRODUCTION OF NICKED CLOSED-ENDED DNA VECTORS Generation Bio Co. (US) 2022-05-25 EP claimed
EP-0726761-A1 MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM ISOTECH MEDICAL, INC. (US) 1996-08-21 EP claimed
EP-0500437-B1 Ceramides, method for their preparation and their application in cosmetics and dermopharmacy OREAL (FR) 1995-07-26 EP claimed
WO-1995012385-A1 MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM ISOTECH MEDICAL, INC. (US) 1995-05-11 WO claimed
EP-0647617-A1 Ceramides, process for their preparation and their cosmetic uses L'OREAL (FR) 1995-04-12 EP claimed
EP-0599977-A1 HIV-TREATMENT METHOD WITH LOW-TOXICITY AMPHOTERICIN B SEQUUS PHARMACEUTICALS, INC. (a Delaware Corporation) (US) 1994-06-08 EP claimed
EP-0420722-B1 Lipid compounds, derivatives of sphingosines, process for their preparation and their use, especially in cosmetics and in dermopharmaceutics OREAL (FR) 1994-02-23 EP claimed
WO-1993003737-A1 HIV-TREATMENT METHOD WITH LOW-TOXICITY AMPHOTERICIN B LIPOSOME TECHNOLOGY, INC. (US) 1993-03-04 WO claimed
EP-0500437-A1 Ceramides, method for their preparation and their application in cosmetics and dermopharmacy L'OREAL (FR) 1992-08-26 EP claimed
EP-0437577-A1 TOPICAL DELIVERY OF PEPTIDES/PROTEINS ENTRAPPED IN DEHYDRATION/REHYDRATION LIPOSOMES THE UNIVERSITY OF MICHIGAN (US) 1991-07-24 EP claimed
WO-1991001719-A1 TOPICAL DELIVERY OF PEPTIDES/PROTEINS ENTRAPPED IN DEHYDRATION/REHYDRATION LIPOSOMES THE UNIVERSITY OF MICHIGAN (US) 1991-02-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281459-A1 LIPIDS, FORMULATIONS, AND USES THEREOF RNMT, INMT, TPH1 CYP46A1 1053/4885NR1H3 1654/4885POLA1 1117/4885
US-20260115129-A1 METHOD FOR INCREASING EFFECTIVE POLYPHENOL COMPONENTS USING HIGH-TEMPERATURE AND PRESSURIZATION STEAM EXTRACTION METHOD TYR, HSF1, NFATC1 CYP46A1 66/4885NR1H3 3388/4885POLA1 3120/4885
US-20240269229-A1 NOVEL LIPOPEPTIDE FORMULATION LPXN, NGLY1, VIP CYP46A1 1337/4885NR1H3 2243/4885POLA1 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.